Edwards Lifesciences Co. (NYSE:EW) Stake Boosted by RFG Advisory LLC

RFG Advisory LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 4,492 shares of the medical research company’s stock after acquiring an additional 244 shares during the period. RFG Advisory LLC’s holdings in Edwards Lifesciences were worth $376,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. RDA Financial Network lifted its stake in shares of Edwards Lifesciences by 13.9% during the fourth quarter. RDA Financial Network now owns 16,843 shares of the medical research company’s stock valued at $1,537,000 after acquiring an additional 2,051 shares during the period. Sarasin & Partners LLP increased its holdings in Edwards Lifesciences by 23.7% in the fourth quarter. Sarasin & Partners LLP now owns 202,149 shares of the medical research company’s stock valued at $18,442,000 after purchasing an additional 38,676 shares during the last quarter. Genesee Capital Advisors LLC increased its holdings in Edwards Lifesciences by 13.3% in the first quarter. Genesee Capital Advisors LLC now owns 26,860 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 3,145 shares during the last quarter. Harbor Group Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $536,000. Finally, KBC Group NV grew its holdings in shares of Edwards Lifesciences by 13.0% during the fourth quarter. KBC Group NV now owns 1,084,248 shares of the medical research company’s stock worth $98,916,000 after buying an additional 124,961 shares in the last quarter. 80.94% of the stock is currently owned by institutional investors.

In related news, Director Nicholas J. Valeriani sold 8,200 shares of the business’s stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $85.21, for a total value of $698,722.00. Following the completion of the sale, the director now directly owns 67,896 shares in the company, valued at approximately $5,785,418.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 3,389 shares of the business’s stock in a transaction on Thursday, April 22nd. The stock was sold at an average price of $94.40, for a total value of $319,921.60. Following the transaction, the vice president now directly owns 30,355 shares of the company’s stock, valued at approximately $2,865,512. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 323,819 shares of company stock worth $27,233,148. 1.48% of the stock is currently owned by insiders.

Shares of EW opened at $96.15 on Friday. Edwards Lifesciences Co. has a 1-year low of $66.23 and a 1-year high of $96.39. The stock has a market capitalization of $59.81 billion, a P/E ratio of 76.92, a P/E/G ratio of 2.61 and a beta of 0.97. The company has a current ratio of 3.52, a quick ratio of 2.61 and a debt-to-equity ratio of 0.14. The business’s 50-day moving average price is $83.62 and its 200 day moving average price is $84.24.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Monday, April 19th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.07. The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Edwards Lifesciences had a return on equity of 29.00% and a net margin of 18.18%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.50 earnings per share. On average, research analysts predict that Edwards Lifesciences Co. will post 1.89 earnings per share for the current year.

Several brokerages have commented on EW. Wells Fargo & Company lifted their target price on Edwards Lifesciences from $87.00 to $93.00 and gave the stock an “equal weight” rating in a report on Wednesday. Morgan Stanley raised their price objective on Edwards Lifesciences from $99.00 to $108.00 and gave the company an “overweight” rating in a research note on Wednesday. Evercore ISI upgraded shares of Edwards Lifesciences from an “in-line” rating to an “outperform” rating in a report on Monday, April 5th. Raymond James raised their price objective on shares of Edwards Lifesciences from $96.00 to $101.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Piper Sandler raised their price objective on shares of Edwards Lifesciences from $97.00 to $105.00 and gave the stock an “overweight” rating in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $94.16.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Story: Short Selling

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.